Investors that missed out on the IPO for medtech company 4D Medical (ASX: 4DX) have had no qualms buying the stock on market with shares in 4DX opening at $1.47 when trading commenced this morning, more than double the IPO Offer Price of $0.73. The significant jump follows a similar trend among Australian investors that
Read More
While the number of companies set to list on the ASX is still quieter than usual, we are continuing to see many healthcare companies viewing COVID-19 as an opportunity to make their public debut. 4D Medical are a Melbourne-based medical technology company, who have spent the last 15 years developing lung imaging software. The ‘software
Read More
Amid the raging situation in Victoria with rising COVID-19 cases in aged care facilities, tech company InteliCare (ASX: ICR) has secured a cornerstone order for their aged and disability care system which enables families to monitor loved ones contact-free, without invading their privacy. The order for 120 InteliLiving Systems was placed by independent care provider
Read More
Smart healthcare continues to make strides in the United Kingdom with healthtech company Alcidion (ASX: ALC) to deploy their Patientrack monitoring system across the NHS Lanarkshire, the third largest health board in Scotland. With approximately 12,000 staff working across communities, health centres, clinics and three district hospitals, the 5-year agreement will see Alcidion roll out
Read More
Soft tissue regeneration company, Aroa Biosurgery, is set to list on the ASX at the end of the month. The company is looking to raise $45m at an offer price of $0.75, ultimately giving the Auckland-based company a proposed market capitalisation of $225m. Aroa’s technology is centred around soft tissue regeneration and the complex wound
Read More
After meeting with the FDA, biopharmaceuticals company Alterity Therapeutics (ASX: ATH) has confirmed Phase II clinical trial plans for their ATH434 compound in the treatment of Multiple System Atrophy (MSA), an incurable Parkinsonian disorder with no regulatory precedent. Due to the unique scenario where there are no accepted efficacy endpoints, guidance has been provided by
Read More